Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM313 in Relapsed/Refractory Multiple Myeloma and Lymphoma
NCT04818372Phase 1Unknown
- Sponsor
- Keymed Biosciences
- Start
- Apr 2021
- Primary completion
- Jan 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of cm313 in multiple myeloma (MM) and lymphoma (3 arms), sponsored by Keymed Biosciences. Primary endpoints: Dose-Limiting Toxicity at 21 days, Treatment Emergent Adverse Events and Serious Adverse Events and 1 more. Status: unknown.
02
Drugs
cm313
03
Conditions
multiple myeloma (MM)lymphoma
Beyond the preview
Go deeper on NCT04818372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04818372.